個人積分：7分
文章編號：81945395
個人積分：1085分
文章編號：81945407
個人積分：3177分
文章編號：81945452
個人積分：1467分
文章編號：81945463
photoshare wrote:
聽你在趴噗，又是中央製圖工廠做的假消息嗎？
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adultshttps://clinicaltrials.gov/ct2/show/NCT04380701
This trial has two parts. Part A and Part B. Due to changes in the overall clinical development plan, Part B will no longer be conducted. The objectives originally described for Part B have been implemented in the ongoing development via a pivotal Phase I/II/III trial BNT162-02/C4591001 (ClinicalTrials.gov NCT: 04368728).
Part A is for dose ranging of four different vaccines (BNT162a1, BNT162b1, BNT162b2, and BNT162c2) which will be undertaken with dose escalation and de-escalation plus the evaluation of interim dose levels. It also includes dose ranging in older participants.
The vaccines BNT162a1, BNT162b1, BNT162b2, and BNT162c2 will be administered using a Prime/Boost (P/B) regimen. The vaccine BNT162c2 will also be administered using a Single dose (SD) regimen. Three additional cohorts aged from 18 to 85 years receiving BNT162b2 only.
BNT162b2 has entered a Phase II/III evaluation of efficacy, with the intent to support an application for marketing authorization. The dosing regimen under investigation is two BNT162b2 doses given ~21 d apart.
維基百科
輝瑞製藥和BioNTech的研發計劃包括四種候選疫苗[52]，分別是BNT162a1、BNT162b1、BNT162b2及BNT162c2[53]，各有不同組合形式的mRNA及目標抗原，並透過第一期及第二期臨床試驗識別最安全及最有效的潛在疫苗[54]。
中央製圖工廠做的假消息，無誤！！！！
個人積分：1085分
文章編號：81945494
個人積分：12474分
文章編號：81945589
個人積分：67分
文章編號：81945615
個人積分：5964分
文章編號：81945641
個人積分：1987分
文章編號：81945652
